Zentalis Pharmaceuticals Amends Director and Officer Filings
Ticker: ZNTL · Form: 8-K/A · Filed: Dec 19, 2024 · CIK: 1725160
Sentiment: neutral
Topics: director-election, amendment, corporate-governance
Related Tickers: ZNTL
TL;DR
Zentalis adds a new director, Lori Friedman, and updates exec comp details.
AI Summary
Zentalis Pharmaceuticals, Inc. filed an 8-K/A on December 19, 2024, to amend a previous filing regarding changes in directors and officers, and compensatory arrangements. The amendment specifically addresses the election of Dr. Lori Friedman as a Class II director, effective December 17, 2024, and updates information related to executive compensation.
Why It Matters
This amendment clarifies changes in the company's board of directors and executive compensation, providing updated information for investors regarding corporate governance.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, primarily updating information on director appointments and compensation, which typically carries low risk.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Registrant
- Lori Friedman (person) — Newly elected Class II director
- December 17, 2024 (date) — Effective date of director election
- December 19, 2024 (date) — Filing date of the 8-K/A
FAQ
What is the primary purpose of this 8-K/A filing?
The primary purpose is to amend a previous Form 8-K filing to update information regarding the departure of directors or certain officers, election of directors, and compensatory arrangements of certain officers.
Who was elected as a new director and when did this take effect?
Dr. Lori Friedman was elected as a Class II director, effective December 17, 2024.
What specific items are being amended or updated in this filing?
The filing amends Item 5.02, which covers the departure of directors or certain officers, election of directors, and appointment of certain officers, as well as Item 5.02(c) regarding compensatory arrangements of certain officers.
What is the filing date of this 8-K/A?
This 8-K/A was filed on December 19, 2024.
What is the exact name of the registrant?
The exact name of the registrant is Zentalis Pharmaceuticals, Inc.
Filing Stats: 560 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-12-19 16:01:43
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
- $7,500 — titled to receive an annual retainer of $7,500 for his service as a member of the Comp
Filing Documents
- zntl-20241217.htm (8-K/A) — 30KB
- 0001725160-24-000193.txt ( ) — 173KB
- zntl-20241217.xsd (EX-101.SCH) — 2KB
- zntl-20241217_def.xml (EX-101.DEF) — 4KB
- zntl-20241217_lab.xml (EX-101.LAB) — 26KB
- zntl-20241217_pre.xml (EX-101.PRE) — 16KB
- zntl-20241217_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: December 19, 2024 By: /s/ Julie Eastland Julie Eastland President and Chief Executive Officer